| abstract |
The present disclosure relates to diarylhydantoin compounds of the formulan nwherein R 3 is selected from the group consisting of,n ncyano, hydrogen, formyl,n nandn nThe rest of the variables is as defined in the claims. nPharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising the same for use in treatment of hormone refractory prostate cancer. |